Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

NCT02279602 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

7

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: fosbretabulin

Sponsor

Mateon Therapeutics